Support the ERS Thoracic Oncology Assembly in their pulmonary toxicity project
The ERS Thoracic Oncology Assembly has launched a project to improve the reporting, understanding and management of pulmonary toxicity caused by the ever-expanding range of targeted and novel therapies in thoracic oncology, across Europe.
The first step is to gain an overview of access to and use of EMA-approved targeted therapies and immunotherapies for lung cancer care in European nations – with a view to understanding the level of knowledge of the respiratory community around how toxicities link to the use of these new therapies.
The Assembly has developed a short survey to support this process and would be grateful if you could support the initial stages of this project by taking the time to complete it.
As a second step, the Assembly would like to develop an online platform for connecting physicians around Europe involved in the management of toxicity from the growing range of new systemic therapies in lung cancer. This user friendly platform will allow a quick and easy method for reporting toxicities from "real life" practice and keep physicians up to date with the latest developments surrounding these therapies. It will act as a source of information and a platform for exchanging ideas and questions about these new drugs.
ALSO…
The ERS Thoracic Oncology Assembly would also like to encourage you to participate in the ongoing Lung Cancer Europe (LuCE) survey, which is asking for input from both professionals and patient advocates. The surveys are intended to gather information about lung cancer policy and access to treatment across Europe, for an upcoming report.